Compounds > 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic-acid

2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic-acid and Arteriosclerosis

2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic-acid has been researched along with Arteriosclerosis* in 1 studies

Other Studies

1 other study(ies) available for 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic-acid and Arteriosclerosis

Article	Year
OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro. Prostaglandins, 1981, Volume: 22, Issue:3 OKY-1581 is an effective inhibitor of thromboxane synthesis in vivo and in vitro. The generation of thromboxane B2 (TxB2), prostaglandin E (PGE) and prostaglandin F (PGF) was measured following clotting and during platelet aggregation induced by collagen. The presence of OKY 1581 either in vivo or in vitro caused a reduction in TxB2 generation during clotting and platelet aggregation with a concomitant increase in PGE and PGF. The effect could be observed two hours after oral or subcutaneous administration of 5 to 100 mg per rabbit and lasted for 24 to 48 hours. The reduction in TxB2 was not accompanied by an inhibition of clotting or platelet aggregation. OKY-1581 appears to be a suitable agent for studying the role of TxB2 in atherosclerosis. Topics: Acrylates; Animals; Arteriosclerosis; Blood Platelets; In Vitro Techniques; Male; Methacrylates; Platelet Aggregation; Prostaglandins E; Prostaglandins F; Rabbits; Thromboxane B2; Thromboxanes	1981

Article

Year

OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro.

Prostaglandins, 1981, Volume: 22, Issue:3

OKY-1581 is an effective inhibitor of thromboxane synthesis in vivo and in vitro. The generation of thromboxane B2 (TxB2), prostaglandin E (PGE) and prostaglandin F (PGF) was measured following clotting and during platelet aggregation induced by collagen. The presence of OKY 1581 either in vivo or in vitro caused a reduction in TxB2 generation during clotting and platelet aggregation with a concomitant increase in PGE and PGF. The effect could be observed two hours after oral or subcutaneous administration of 5 to 100 mg per rabbit and lasted for 24 to 48 hours. The reduction in TxB2 was not accompanied by an inhibition of clotting or platelet aggregation. OKY-1581 appears to be a suitable agent for studying the role of TxB2 in atherosclerosis.

Topics: Acrylates; Animals; Arteriosclerosis; Blood Platelets; In Vitro Techniques; Male; Methacrylates; Platelet Aggregation; Prostaglandins E; Prostaglandins F; Rabbits; Thromboxane B2; Thromboxanes

1981